Chiome Bioscience Inc. announced that the first patient has been dosed CBA-1535 in a Phase I clinical trial. The first part of the trial will evaluate the safety, tolerability, pharmacokinetics, and identification of biomarker for the solid tumor patients. In the expansion part, exploratory efficacy will be evaluated in combination with cancer immunotherapy agent Pembrolizumab.

This first-in-human study is conducted at National Cancer Center Hospital and Shizuoka Cancer Center. Will continue to update the future process in a timely manner.